Novo Nordisk AS ADR | - | 16.72% | - | - | 87,953 |
LLY | 15.40% | 771.71 | +1.34% | 6,948 | |
Metsera Inc | - | 5.23% | - | - | 40,528 |
VKTX | 5.00% | 32.010 | -0.19% | 53,514 | |
ROG | 4.85% | 258.50 | +0.58% | 5,222 | |
ZELA | 4.58% | 363.10 | +1.09% | 28,213 | |
Innovent Biologics Inc | - | 4.41% | - | - | 133,500 |
PFE | 4.03% | 24.47 | -0.45% | 56,319 | |
4519 | 4.00% | 7,004.0 | +1.21% | 29,500 | |
Terns Pharmaceuticals Inc Ordinary Shares | - | 3.71% | - | - | 227,847 |
Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF is an exchange traded fund launched and managed by Roundhill Financial Inc. The fund is co-managed by Exchange Traded Concepts, LLC. It invests in public equity markets. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, pharmaceuticals, pharmaceutical drugs designed for weight loss and anti-obesity, GLP-1 receptor agonists and GLP-1 & weight loss sectors. The fund invests in growth and value stocks of companies operating across diversified market capitalization. The fund employs proprietary research to create its portfolio. Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF was formed on March 31, 2024 and is domiciled in the United States.